Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating today.
Serge Belanger has given his Buy rating due to a combination of factors, primarily focusing on the strong performance and growth prospects of BioCryst’s key product, Orladeyo. The company reported impressive first-quarter revenues for 2025, surpassing market expectations significantly. This was largely driven by an unexpected increase in the paid prescription rate for Orladeyo, which benefited from reduced Medicare copayments.
Looking ahead, the durability of this increased prescription rate is expected to support higher sales guidance for Orladeyo, with projections for 2025 sales being raised considerably. Additionally, the potential for further growth is bolstered by ongoing improvements in new patient additions and anticipated expansion into pediatric markets in 2026. These factors contribute to a valuation that Belanger believes does not fully reflect Orladeyo’s robust growth potential, prompting an increase in the price target for BioCryst’s stock.
Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, BioCryst, and Esperion. According to TipRanks, Belanger has an average return of 1.7% and a 41.54% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.